C4 Therapeutics Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

C4 Therapeutics Stock Summary

C4 Therapeutics competes with Shattuck Labs, Prelude Therapeutics, Monte Rosa, Foghorn Therapeutics, and Rezolute. C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. C4 Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 121 people.

C4 Therapeutics Key Financial Ratios

C4 Therapeutics Key Balance Sheet Accounts

C4 Therapeutics Key Income Statement Accounts

C4 Therapeutics Key Cash Accounts

CCCC Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining C4 Therapeutics's current stock value. Our valuation model uses many indicators to compare C4 Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across C4 Therapeutics competition to find correlations between indicators driving C4 Therapeutics's intrinsic value. More Info.C4 Therapeutics is rated below average in return on equity category among its peers. It is rated fourth in return on asset category among its peers . At present, C4 Therapeutics' Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the C4 Therapeutics' earnings, one of the primary drivers of an investment's value.

C4 Therapeutics Systematic Risk

Today, most investors in C4 Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various C4 Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of C4 Therapeutics growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of C4 Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of C4 Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of C4 Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing CCCC Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build C4 Therapeutics's daily price indicators and compare them against related drivers.

When running C4 Therapeutics' price analysis, check to measure C4 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy C4 Therapeutics is operating at the current time. Most of C4 Therapeutics' value examination focuses on studying past and present price action to predict the probability of C4 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move C4 Therapeutics' price. Additionally, you may evaluate how the addition of C4 Therapeutics to your portfolios can decrease your overall portfolio volatility.